What happened with WHWK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Whitehawk Therapeutics is developing treatments that attach a cancer-killing drug to an antibody designed to recognize tumor cells. These antibody-drug conjugates, or ADCs, are intended to deliver the drug inside those cells. Its current candidates have not entered human trials. Whitehawk licensed worldwide development and commercialization rights from WuXi Biologics, using Hangzhou DAC’s CPT113 linker-payload technology.
The company previously earned product revenue from FYARRO, a treatment for a rare cancer called malignant PEComa. It sold that business to KAKEN in March 2025 and no longer sells FYARRO. Cash from the sale and stock financing supports the transition to drug development; Whitehawk needs additional funding to complete development. Future product sales depend on successful trials and regulatory approval, which is required before it can market its candidates.
Whitehawk relies on WuXi Biologics for antibodies and much of the manufacturing preparation needed for trials, and on Hangzhou DAC for the linker-payload component. Its rights also depend on maintaining the WuXi license, which carries development obligations, milestone payments and royalties on eventual sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
After divesting FYARRO, Whitehawk’s prospects hinge on its ADC clinical results and its reliance on WuXi Biologics and Hangzhou DAC for licensed technology and manufacturing.
AbbVie’s ABBV-706 directly challenges Whitehawk’s HWK-206: both use antibodies to deliver cancer-killing drugs to cells bearing SEZ6. Watch ABBV-706’s clinical results; Whitehawk’s claimed advantage from binding two sites on SEZ6 rests on preclinical evidence, not patient results.
IDEAYA Biosciences’ IDE034 competes with Whitehawk’s HWK-007 by using an antibody to deliver a TOP1-inhibiting cancer drug, but targets both PTK7 and B7H3 rather than PTK7 alone. Its Phase 1 results offer a clinical comparison point for HWK-007 in a field where Whitehawk reports no approved PTK7 ADC.
Eli Lilly’s LY4175408 competes with Whitehawk’s HWK-007 by using an antibody to deliver an exatecan cancer-drug payload to PTK7-bearing cells. Watch its Phase 1 results: Whitehawk’s reported preclinical advantage for HWK-007 was against an older PTK7 ADC, not Lilly’s candidate.
Regeneron pursues the same MUC16 tumor marker as Whitehawk’s HWK-016, but its antibodies recruit T cells rather than deliver a cancer-drug payload. Responses to Regeneron’s two MUC16 programs are worth watching; Whitehawk cites modest response rates so far as a limitation of that approach.
NextCure and Whitehawk both rely on licensed cancer-drug pipelines that use antibodies to deliver TOP1 inhibitors and aim to release them selectively in tumors. NextCure’s SIM0505 efficacy and safety results offer a comparison for that strategy, though it targets CDH6 rather than Whitehawk’s targets.
Zymeworks and Whitehawk both need their antibody-delivered cancer drugs to demonstrate better efficacy and safety to establish their portfolios’ value. Zymeworks also receives milestone payments and royalties from licensing partners, making clinical progress and licensing deals for its wholly owned ADCs worth watching alongside Whitehawk’s still-preclinical improvement claims.
Pyxis Oncology and Whitehawk both seek to make antibody-delivered cancer drugs more stable and reduce harmful drug release outside tumors through how the drug is attached to the antibody. Pyxis has concentrated development on MICVO, making its clinical safety and efficacy results the clearest test to watch for this design strategy.
Eli Lilly & Co. earningsLLY
If Lilly reports Phase 1 results for LY4175408, its report will show what clinical benchmark this PTK7-targeting antibody-drug conjugate sets for Whitehawk’s HWK-007.
Look for LY4175408’s anti-tumor activity and safety in patients, and keep those human results separate from Whitehawk’s preclinical findings for HWK-007. Activity with manageable safety would make the clinical bar facing HWK-007 clearer and higher; weak results could ease that comparison, but would not prove HWK-007 works, since it has no human results and the drugs are not being tested head to head.
ABBVIE INC. earningsABBV
If AbbVie reports clinical results for ABBV-706, its report will show what competitive clinical benchmark this SEZ6-targeting antibody-drug conjugate sets for Whitehawk’s HWK-206.
Look for signs of patient benefit and safety with ABBV-706. Strong findings on both would set a higher human-clinical benchmark for SEZ6-targeting antibody-drug conjugates, leaving HWK-206 to establish its value with its own results; weaker findings would soften that competitive signal but would not show how HWK-206 will perform.
Regeneron Pharmaceuticals Inc earningsREGN
If Regeneron updates results from its MUC16 programs, its report will show whether this tumor marker is linked to patient responses, offering a different-approach comparison for Whitehawk’s HWK-016.
Look at patient responses reported for Regeneron’s two MUC16 programs. Clear responses would support MUC16 as a clinically relevant target; limited responses would raise questions about the target or Regeneron’s T-cell-recruiting approach. Whitehawk’s HWK-016 uses an antibody-drug conjugate, so the results are not directly comparable, but they help readers judge whether MUC16 itself merits attention.
Pyxis Oncology, Inc. earningsPYXS
If Pyxis Oncology updates MICVO’s clinical safety and efficacy, its report will show how an antibody-drug design like Whitehawk’s is performing in patients.
Look for safety and efficacy signals for MICVO in patients, especially whether the antibody-drug attachment appears to limit harm from drug release outside tumors. Results showing both safety and activity would offer a clinical reference for Whitehawk’s design goal; poor results would show that the design may not, by itself, overcome the risks, but would not determine how Whitehawk’s candidates perform.
Whitehawk Therapeutics, Inc. earningsThis company
Whitehawk Therapeutics no longer sells FYARRO, so its report will show whether spending to advance its antibody-drug candidates is accelerating its cash use.
Read research and development spending alongside cash used in operations, then compare both with cash, cash equivalents and short-term investments on hand. Higher development spending accompanied by progress and cash use still consistent with the company’s stated plan would suggest the work is advancing without sharply eroding its funding cushion; faster cash use with little progress would point to financing pressure arriving sooner.
